Goodman Fielder Wattie Ltd v Commissioner of Taxation

Goodman Fielder Wattie Ltd initiated an appeal against the Commissioner of Taxation concerning deductions disallowed for research and development expenses related to monoclonal antibodies. The dispute involved whether the taxpayer was carrying on a business and whether the expenses were incurred in gaining or producing assessable income, as required by sections 51(1) and 73A(1) of the Income Tax Assessment Act 1936. The court was tasked with determining the eligibility of these expenses as tax deductions. The primary legal issue revolved around the interpretation of what constitutes a business and whether the activities in question were sufficiently connected to the production of assessable income to warrant the deductions claimed. The court had to assess whether the research and development activities undertaken by Goodman Fielder Wattie Ltd were part of a business aimed at generating income or if they were isolated, non-commercial scientific pursuits.

The Federal Court, after thorough examination, concluded that the taxpayer was indeed carrying on a business within the meaning of the relevant sections of the Income Tax Assessment Act 1936. The court found that the activities related to the research and development of monoclonal antibodies were integral to the taxpayer's broader business operations and were aimed at enhancing its commercial capabilities. Consequently, the expenses incurred in these activities were considered deductible as they were necessary to produce assessable income. The court emphasised the importance of the commercial intent and the ongoing nature of the activities in reaching its decision.

The court's ruling led to the dismissal of the appeal for the year of income ended 30 June 1982, while allowing the appeals for the years ended 30 June 1983, 1984, and 1985 in part. The assessments for these latter years were remitted to the Commissioner for amendment in line with the court's reasoning. The matter was adjourned to 22 May 1991 for further argument on costs, with the costs of the adjourned hearing to be borne by the applicant.